Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 314 clinical trials
A Phase 2 Study to Evaluate the Efficacy and Safety of MK-1026 in Participants With Hematologic Malignancies

The purpose of this study is to evaluate the safety and efficacy of nemtabrutinib (formerly ARQ 531) in participants with hematologic malignancies of chronic lymphocytic leukemia (CLL)/ small

lymphoma
mantle cell lymphoma
measurable disease
hepatitis b surface antigen
leukemia
  • 33 views
  • 28 Oct, 2022
  • 45 locations
A Phase 1/2, Open-Label Safety Trial of GEN3013 in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma EPCORE™NHL-1

The trial is a global, multi-center safety trial of Epcoritamab, an antibody also known as GEN3013 (DuoBody®-CD3xCD20). The trial consists of three parts: a dose-escalation part (Phase 1, first-in-human (FIH)), an expansion part (Phase 2a) and a dose optimization part (Phase 2a)

monoclonal protein
follicular lymphoma
high grade b-cell lymphoma
renal function tests
chronic lymphocytic leukemia
  • 324 views
  • 27 Oct, 2022
  • 91 locations
First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas

The drug that will be investigated in the study is an antibody, GEN3009. Since this is the first study of GEN3009 in humans, the main purpose is to evaluate safety. Besides safety, the study will determine the recommended GEN3009 dose to be tested in a larger group of patients and …

hodgkin's disease
btk inhibitor
measurable disease
leukemia
beta human chorionic gonadotropin
  • 17 views
  • 04 Oct, 2022
  • 14 locations
Safety & Efficacy Study of Epcoritamab in Subjects With R/R Chronic Lymphocytic Leukemia and Richter's Syndrome (EPCORE CLL-1)

The trial is an open-label, multi-center safety and efficacy trial of epcoritamab in relapsed/refractory chronic lymphocytic leukemia (R/R CLL) and Ritcher's Syndrome (RS). The trial consists of

  • 0 views
  • 30 Jun, 2022
  • 22 locations
  • 17 views
  • 04 May, 2022
  • 8 locations
A Phase 1 Study of Oral LOXO-338, a Selective BCL-2 Inhibitor, in Patients With Advanced Hematologic Malignancies

The purpose of this study is to find out whether the study drug, LOXO-338, is safe and effective in patients with advanced blood cancer. Patients must have already received standard therapy. The study may last up to approximately 3 years.

cancer
measurable disease
bone marrow procedure
  • 0 views
  • 23 Oct, 2022
  • 21 locations
A Phase I, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Patients With Relapsed or Refractory Lymphoma

This is a Phase I, open-label, multicenter study of HMPL-523 administered orally to patients with relapsed or refractory lymphoma who have exhausted approved therapy options. This study consists of a dose escalation stage (Stage1) and a dose expansion stage (Stage 2).

marginal zone lymphoma
waldenstrom's macroglobulinemia
refractory lymphoma
leukemia
follicular lymphoma
  • 0 views
  • 24 Oct, 2022
  • 21 locations
In Vivo Metabolic Profiling of CLL (Chronic Lymphocytic Leukemia)

quantitatively characterize metabolic signatures and fuel preferences of leukemic lymphocytes in patients with chronic lymphocytic leukemia (CLL). Isotopic metabolic tracers are nutrients that are chemically

cancer
chronic lymphocytic leukemia
cytopenia
lymphocytosis
Accepts healthy volunteers
  • 0 views
  • 03 Jul, 2022
  • 1 location
Zanubrutinib and Rituximab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

This phase II trial studies how well zanubrutinib and rituximab work in treating patients with chronic lymphocytic leukemia or small lymphocytic lymphoma for which the patient has not received

lymphoma
btk inhibitor
gilbert's syndrome
monoclonal protein
cancer
  • 0 views
  • 04 Oct, 2022
  • 1 location
Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

This phase II trial tests whether acalabrutinib, venetoclax, and durvalumab work in treating patients with Richter transformation from chronic lymphocytic leukemia or small lymphocytic lymphoma

lymphoma
measurable disease
lymphadenopathy
venetoclax
platelet count
  • 0 views
  • 02 Jul, 2022
  • 1 location